International Journal of Pharmacognosy (IJP)的动态

POLYPHARMACY PARADOX: UNRAVELING ENTERIC ULCER CONUNDRUM Polypharmacy, the concurrent use of multiple medications by a single patient, is common in modern healthcare to manage multiple comorbidities. While it helps address complex health conditions, it also brings significant challenges, such as increased risks of drug interactions and adverse effects, including the development of enteric ulcer lesions in the gastrointestinal tract. Read complete article here: https://lnkd.in/gSzphiwd Follow our other media handles: International Journal of Pharmaceutical Sciences and Research (IJPSR) Society of Pharmaceutical Sciences and Research (SPSR) International Journal of Pharmacognosy (IJP) #spsr #researcharticle #ijpsr #ijp

POLYPHARMACY PARADOX: UNRAVELING ENTERIC ULCER CONUNDRUM #Polypharmacy, the concurrent use of multiple medications by a single patient, is common in modern healthcare to manage multiple comorbidities. While it helps address complex health conditions, it also brings significant challenges, such as increased risks of drug interactions and adverse effects, including the development of enteric ulcer lesions in the gastrointestinal tract. Read complete article here: https://lnkd.in/gSzphiwd Follow our other media handles: International Journal of Pharmaceutical Sciences and Research (IJPSR) Society of Pharmaceutical Sciences and Research (SPSR) International Journal of Pharmacognosy (IJP) SPSR Periodicals Pvt Ltd #spsr #researcharticle #ijpsr #ijp

FDA has granted approval to EOHILIA (Budesonide oral suspension) by Takeda for patients aged 11 years and older with Eosinophilic Esophagitis (EoE). It is the first and only FDA approved therapy for this indication. The approval is based on data from two double-blind, placebo-controlled 12-wk clinical trials (Histologic remission of 53.1% vs 1% in placebo arm in Study 1 and 38% vs 2.4% in placebo arm in Study 2) As per the company PR, The oral suspension will be available in 2mg/10mL single-dose stick packs by the end of february Prescribing information (https://bit.ly/3UEUzcO) indicates that use of EOHILIA for more than 12 weeks has not been shown to be safe and effective for the treatment of Eosinophilic Esophagitis. https://bit.ly/49yLVRq #esophagitis #takeda #corticosteroids #fda #fdaapproval #competitiveintelligence #pharma #pharmaceutical #biotech #healthcare #lifesciences #lifesciencesconsulting

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) Cohort Dosing Complete Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial ? Dosing of 6 human subjects complete in Phase I/II UTI/Urosepsis fast infusion intravenous study of RECCE? 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in this clinical trial ? Independent Safety Committee to review cohort data with preliminary results expected in near weeks ? Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples, a dose optimisation exercise for regulatory purposes CEO: James Graham recce.com.au #biotech #pharmaceuticals #superbugs #antiviral #antibiotics #antibioticresistance

Check out and subscribe to our BioPharmCatalyst Weekly Watchlist! Stay on top of which companies have key upcoming data readouts and regulatory decisions for the quarter. Weekly Watchlist Recap for June 15th, 2024: -The FDA has extended the Priority Review period for Rocket Pharmaceuticals' (RCKT) BLA filing for KRESLADI, targeting LAD-I, to June 30th, 2024. -Verona Pharma (VRNA) has a PDUFA target action date for ensifentrine, targeting chronic obstructive pulmonary disease, set for June 26, 2024. -Jazz Pharmaceutical (JAZZ) will have a top-line data readout for its Phase 2b trial of suvecaltamide, targeting essential tremor, in late first half of 2024. https://lnkd.in/epJ_t-Qc #watchlist #biotechinvesting #catalysts #fasterscience #clinicaltrials #datareadout #pharma #biotech #biotechstocks

Despite the summer months being slower for most industries, there is still plenty to be excited about in the way of biotech investing in the coming months. Check out our key upcoming catalysts for the quarter to see which companies have important data readouts and regulatory decisions coming up!

Alembic Pharma Celebrates: USFDA Approval for Psoriasis Drug Acitretin Capsules! We are thrilled to announce that Alembic Pharmaceuticals has received approval from the US Food and Drug Administration (USFDA) for our Acitretin Capsules, used in the treatment of severe psoriasis. This milestone underscores our commitment to bringing innovative and effective treatments to patients worldwide. Our latest blog post, "Alembic Pharma Celebrates: USFDA Approval for Psoriasis Drug Acitretin Capsules!" explores the significance of this approval, the impact on our portfolio, and how it advances our mission to improve patient outcomes. https://lnkd.in/ew_adFxA #AlembicPharma #USFDAApproval #Pharmaceuticals #HealthcareInnovation #PsoriasisTreatment #MedicalAdvancements #PharmaNews #PatientCare #GlobalHealth #Acitretin #Youtubeshorts #Shorts #Facebook #Linkedln Join us in celebrating this achievement! Share your thoughts on the importance of innovative treatments for psoriasis in the comments below. If you’re excited about this news, like and share this post to spread the word about Alembic Pharma’s latest success.

AN UPDATED ANALYSIS OF ETIOLOGIES AND PROGNOSIS OF 30-DAY READMISSION IN HEART FAILURE The prevalence of Heart Failure (HF) is expected to rise over the next few decades, placing a significant strain on the healthcare system. Exact risk stratification in HF?is still difficult, even though?numerous prognostic markers of death and/or HF?hospitalization have been found in HF patients; nonetheless, their practical usefulness is restricted. Read complete article here: https://lnkd.in/gfq5Tgr9 Follow our other media handles: International Journal of Pharmaceutical Sciences and Research (IJPSR) Society of Pharmaceutical Sciences and Research (SPSR) International Journal of Pharmacognosy (IJP) SPSR Periodicals Pvt Ltd #spsr #researcharticle #ijpsr #ijp #heartfailure

?Do you know which was the first transdermal patch on the market? In the history of pharmaceutical innovations, transdermal patches were a huge breakthrough and have already improved the lives of many patients. Back in the 1980s, the first transdermal patch emerged onto the US market, heralding a new era in medication delivery. Containing scopolamine, this patch (Transderm Scōp?) was a game-changer for individuals battling motion sickness. ?A nice anecdote: When the patch was being developed, a team of adventurous pharmaceutical pioneers from the developing company tested the patch first on themselves during a sailboat journey near the iconic Golden Gate Bridge. They found that employees with the patch did not get seasick, whereas those with the placebo patch had to fight motion sickness. Since then, patches have encountered numerous indications. If you want to read more about the role of transdermal patches on the market, our article is waiting for you: https://lnkd.in/e9Z37x6P #AdhexPharma #Innovation #Transdermalpatches #Didyouknow #Pharmaceutical #Pharma

AN UPDATED ANALYSIS OF ETIOLOGIES AND PROGNOSIS OF 30-DAY READMISSION IN HEART FAILURE The prevalence of Heart Failure (HF) is expected to rise over the next few decades, placing a significant strain on the healthcare system. Exact risk stratification in HF?is still difficult, even though?numerous prognostic markers of death and/or HF?hospitalization have been found in HF patients; nonetheless, their practical usefulness is restricted. Read complete article here: https://lnkd.in/gfq5Tgr9 Follow our other media handles: International Journal of Pharmaceutical Sciences and Research (IJPSR) Society of Pharmaceutical Sciences and Research (SPSR) International Journal of Pharmacognosy (IJP) SPSR Periodicals Pvt Ltd #spsr #researcharticle #ijpsr #ijp #heartfailure